GILD logo

GILD
Gilead Sciences, Inc.

77,729
Mkt Cap
$186.25B
Volume
2.9M
52W High
$157.29
52W Low
$93.37
PE Ratio
22.12
GILD Fundamentals
Price
$147.25
Prev Close
$150.03
Open
$149.36
50D MA
$135.87
Beta
0.37
Avg. Volume
7.91M
EPS (Annual)
$6.78
P/B
8.20
Rev/Employee
$1.73M
$169,882.70
Loading...
Loading...
News
all
press releases
Pharmaceutical Stocks To Watch Today - March 3rd
Eli Lilly and Company, Novo Nordisk A/S, Rapt Therapeutics, AbbVie, Gilead Sciences, Bristol Myers Squibb, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...
MarketBeat·33m ago
News Placeholder
More News
News Placeholder
Victory Capital Management Inc. Boosts Stake in Gilead Sciences, Inc. $GILD
Victory Capital Management Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% during the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·5h ago
News Placeholder
Teachers Retirement System of The State of Kentucky Sells 18,145 Shares of Gilead Sciences, Inc. $GILD
Teachers Retirement System of The State of Kentucky lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.8% during the 3rd quarter, according to the company in its most...
MarketBeat·5h ago
News Placeholder
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion PR Newswire VANCOUVER, BC, March 3, 2026...
PR Newswire·5h ago
News Placeholder
Gilead Sciences (NASDAQ:GILD) Stock Acquired Rep. Josh Gottheimer
Representative Josh Gottheimer (Democratic-New Jersey) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on February 26th, the Representative disclosed that they...
MarketBeat·11h ago
News Placeholder
Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, February 27th. The shares were sold at an...
MarketBeat·21h ago
News Placeholder
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·1d ago
News Placeholder
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Gilead Foundation today announced a $12 million investment in 33 communitybased organizations across 14 states and the District of Columbia through its Community Health Worker (CHW) Comprehensive HIV...
Business Wire·1d ago
News Placeholder
Pharmaceutical Stocks To Research - March 1st
Eli Lilly and Company, AbbVie, Gilead Sciences, Abbott Laboratories, Bristol Myers Squibb, Pfizer, and McKesson are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...
MarketBeat·2d ago
News Placeholder
Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V.
APG Asset Management N.V. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.9% during the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·2d ago
<
1
2
...
>

Latest GILD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.